<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35296346</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1479-5876</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>16</Day></PubDate></JournalIssue><Title>Journal of translational medicine</Title><ISOAbbreviation>J Transl Med</ISOAbbreviation></Journal><ArticleTitle>Autoimmunity is a hallmark of post-COVID syndrome.</ArticleTitle><Pagination><StartPage>129</StartPage><MedlinePgn>129</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">129</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-022-03328-4</ELocationID><Abstract><AbstractText>Autoimmunity has emerged as a characteristic of the post-COVID syndrome (PCS), which may be related to sex. In order to further investigate the relationship between SARS-CoV-2 and autoimmunity in PCS, a clinical and serological assessment on 100 patients was done. Serum antibody profiles against self-antigens and infectious agents were evaluated by an antigen array chip for 116 IgG and 104 IgM antibodies. Thirty pre-pandemic healthy individuals were included as a control group. The median age of patients was 49&#xa0;years (IQR: 37.8 to 55.3). There were 47 males. The median post-COVID time was 219 (IQR: 143 to 258) days. Latent autoimmunity and polyautoimmunity were found in 83% and 62% of patients, respectively. Three patients developed an overt autoimmune disease. IgG antibodies against IL-2, CD8B, and thyroglobulin were found in more than 10% of the patients. Other IgG autoantibodies, such as anti-interferons, were positive in 5-10% of patients. Anti-SARS-CoV-2 IgG antibodies were found in&#x2009;&gt;&#x2009;85% of patients and were positively correlated with autoantibodies, age, and body mass index (BMI). Few autoantibodies were influenced by age and BMI. There was no effect of gender on the over- or under-expression of autoantibodies. IgG anti-IFN-&#x3bb; antibodies were associated with the persistence of respiratory symptoms. In summary, autoimmunity is characteristic of PCS, and latent autoimmunity correlates with humoral response to SARS-CoV-2.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rojas</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Carrera 24 # 63c 69, 110010, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez</LastName><ForeName>Yhojan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Carrera 24 # 63c 69, 110010, Bogota, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cl&#xed;nica del Occidente, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acosta-Ampudia</LastName><ForeName>Yeny</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Carrera 24 # 63c 69, 110010, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monsalve</LastName><ForeName>Diana M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Carrera 24 # 63c 69, 110010, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Chengsong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Immunology, Microarray &amp; Immune Phenotyping Core Facility, University of Texas Southwestern Medical Center, Dallas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Quan-Zhen</ForeName><Initials>QZ</Initials><AffiliationInfo><Affiliation>Department of Immunology, Microarray &amp; Immune Phenotyping Core Facility, University of Texas Southwestern Medical Center, Dallas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez-Santana</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Carrera 24 # 63c 69, 110010, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anaya</LastName><ForeName>Juan-Manuel</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-6444-1249</Identifier><AffiliationInfo><Affiliation>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Carrera 24 # 63c 69, 110010, Bogota, Colombia. juan.anaya@urosario.edu.co.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cl&#xed;nica del Occidente, Bogota, Colombia. juan.anaya@urosario.edu.co.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ABN011/IV-FBG001</GrantID><Agency>Universidad del Rosario</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Transl Med</MedlineTA><NlmUniqueID>101190741</NlmUniqueID><ISSNLinking>1479-5876</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Transl Med. 2021 Dec 30;19(1):524. doi: 10.1186/s12967-021-03184-8</RefSource><PMID Version="1">34965855</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="Y">Autoimmunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antigen array</Keyword><Keyword MajorTopicYN="N">Autoantibodies</Keyword><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Latent autoimmunity</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-COVID</Keyword><Keyword MajorTopicYN="N">Post-COVID syndrome</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>17</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35296346</ArticleId><ArticleId IdType="pmc">PMC8924736</ArticleId><ArticleId IdType="doi">10.1186/s12967-022-03328-4</ArticleId><ArticleId IdType="pii">10.1186/s12967-022-03328-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodr&#xed;guez Y, Zapata E, Ram&#xed;rez-Santana C, et al. Persistent autoimmune activation and proinflammatory state in post-COVID syndrome. J Infect Dis. 2022;1:jiac017. doi: 10.1093/infdis/jiac017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac017</ArticleId><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="pubmed">35079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12:5417. doi: 10.1038/s41467-021-25509-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya J-M, Monsalve DM, Rojas M, Rodr&#xed;guez Y, Montoya-Garc&#xed;a N, Mancera-Navarro LM, et al. Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19. J Transl Autoimmun. 2021;4:100091. doi: 10.1016/j.jtauto.2021.100091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100091</ArticleId><ArticleId IdType="pmc">PMC7920824</ArticleId><ArticleId IdType="pubmed">33681751</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6:1. doi: 10.1126/sciimmunol.abl4340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl4340</ArticleId><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Ebinger JE, Mostafa R, Budde P, Gajewski J, Walker B, et al. Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection. J Transl Med. 2021;19:524. doi: 10.1186/s12967-021-03184-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-021-03184-8</ArticleId><ArticleId IdType="pmc">PMC8716184</ArticleId><ArticleId IdType="pubmed">34965855</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya J-M, Rojas M, Salinas ML, Rodr&#xed;guez Y, Roa G, Lozano M, et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021;20:102947. doi: 10.1016/j.autrev.2021.102947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102947</ArticleId><ArticleId IdType="pmc">PMC8428988</ArticleId><ArticleId IdType="pubmed">34509649</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022 (In press).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma W-T, Chang C, Gershwin ME, Lian Z-X. Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review. J Autoimmun. 2017;83:95&#x2013;112. doi: 10.1016/j.jaut.2017.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2017.07.003</ArticleId><ArticleId IdType="pubmed">28739356</ArticleId></ArticleIdList></Reference><Reference><Citation>Tob&#xf3;n GJ, Pers J-O, Ca&#xf1;as CA, Rojas-Villarraga A, Youinou P, Anaya J-M. Are autoimmune diseases predictable? Autoimmun Rev. 2012;11:259&#x2013;66. doi: 10.1016/j.autrev.2011.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2011.10.004</ArticleId><ArticleId IdType="pubmed">22001417</ArticleId></ArticleIdList></Reference><Reference><Citation>Camacho-Dom&#xed;nguez L, Rodr&#xed;guez Y, Polo F, Restrepo Gutierrez JC, Zapata E, Rojas M, et al. COVID-19 vaccine and autoimmunity. A new case of autoimmune hepatitis and review of the literature. J Transl Autoimmun. 2022;1:10014.0. doi: 10.1016/j.jtauto.2022.100140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2022.100140</ArticleId><ArticleId IdType="pmc">PMC8730708</ArticleId><ArticleId IdType="pubmed">35013724</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lorenzo A, Tarsitano MG, Falcone C, Di Renzo L, Romano L, Macheda S, et al. Fat mass affects nutritional status of ICU COVID-19 patients. J Transl Med. 2020;18:299. doi: 10.1186/s12967-020-02464-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02464-z</ArticleId><ArticleId IdType="pmc">PMC7397427</ArticleId><ArticleId IdType="pubmed">32746930</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire D, Woods M, Richards C, Dolan R, Veitch JW, Sim WMJ, et al. Prognostic factors in patients admitted to an urban teaching hospital with COVID-19 infection. J Transl Med. 2020;18:354. doi: 10.1186/s12967-020-02524-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02524-4</ArticleId><ArticleId IdType="pmc">PMC7491021</ArticleId><ArticleId IdType="pubmed">32933530</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>